A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates
- 651 Downloads
Recently, a covariate model characterizing developmental changes in clearance of amikacin in neonates has been developed using birth bodyweight and postnatal age. The aim of this study was to evaluate whether this covariate model can be used to predict maturation in clearance of other renally excreted drugs.
Five different neonatal datasets were available on netilmicin, vancomycin, tobramycin and gentamicin. The extensively validated covariate model for amikacin clearance was used to predict clearance of these drugs. In addition, independent reference models were developed based on a systematic covariate analysis.
The descriptive and predictive properties of the models developed using the amikacin covariate model were good, and fairly similar to the independent reference models (goodness-of-fit plots, NPDE). Moreover, similar clearance values were obtained for both approaches. Finally, the same covariates as in the covariate model of amikacin, i.e. birth bodyweight and postnatal age, were identified on clearance in the independent reference models.
This study shows that pediatric covariate models may contain physiological information since information derived from one drug can be used to describe other drugs. This semi-physiological approach may be used to optimize sparse data analysis and to derive individualized dosing algorithms for drugs in children.
KEY WORDSdevelopmental changes extrapolation glomerular filtration rate neonates pharmacokinetics
Glomerular filtration rate
Normalized prediction distribution error method
ACKNOWLEDGMENTS AND DISCLOSURES
This study was performed within the framework of Top Institute Pharma project number D2-104. The clinical research of Karel Allegaert is supported by the Fund for Scientific Research, Flanders (Clinical Fellowship 1800214N) and has been supported by an IWT-SBO project (130033). The clinical research of J. van den Anker is supported by NIH grants (R01HD060543, K24DA027992, R01HD048689, U54HD071601) and FP7 grants TINN (223614), TINN2 (260908), NEUROSIS (223060), and GRIP (261060). The authors also would like to thank LAP&P Consultants for their technical support with NONMEM.
- 6.FDA C. Guidance for industry. General considerations for pediatric pharmacokinetic studies for drugs and biological products (Draft Guidance). 1998 [20 February 2013]; Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072114.pdf.
- 7.FDA C. Guidance for industry. Population pharmacokinetics. 1999; Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072137.pdf.
- 14.Krekels EHJ, Neely M, Panoilia E, Tibboel D, Capparelli E, Danhof M, et al. From pediatric covariate model to semiphysiological function for maturation: part I—extrapolation of a covariate model from morphine to zidovudine. CPT: Pharmacometrics & Systems Pharmacology. 2012;1:e9. doi: 10.1038/psp201211. Published online 3 October 2012.Google Scholar
- 15.Krekels EHJ, Johnson TN, den Hoedt SM, Rostami-Hodjegan A, Danhof M, Tibboel D, et al. From pediatric covariate model to semiphysiological function for maturation: part II—sensitivity to physiological and physicochemical properties. CPT: Pharmacometrics & Systems Pharmacology. 2012;1:e10. doi: 10.1038/psp201212. Published online 10 October 2012.Google Scholar
- 23.Montgomery DC, Peck EA. Introduction to linear regression analysis. New York: Wiley; 1982. p. 301–2.Google Scholar
- 31.Pacifici GM, Allegaert K. Clinical pharmacokinetics of vancomycin in the neonate: a review. Clinics (Sao Paulo). 2012;67(7):831–7.Google Scholar
- 33.Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of ‘bottom-up’ vs ‘top-down’ recognition of covariates. Drug Metab Pharmacokinet. 2009;24(1):53–75.PubMedCrossRefGoogle Scholar
- 34.Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth. 2011;21(3):291–301.PubMedCrossRefGoogle Scholar
- 35.Allegaert K, Smits A, van den Anker JN. Physiologically based pharmacokinetic modeling in pediatric drug development: a clinician’s request for a more integrated approach. J Biomed Biotechnol. 2012;103763.Google Scholar